CA Patent

CA3094079A1 — Methods of treating cancer in pediatric patients

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2019-09-26 · 7y expired

What this patent protects

Provided herein are methods for treating cancers (e.g., inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, and neuroblastoma) in pediatric patients using brigatinib, as monotherapy or combination therapy with one or more second therapeutic agents.

USPTO Abstract

Provided herein are methods for treating cancers (e.g., inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, and neuroblastoma) in pediatric patients using brigatinib, as monotherapy or combination therapy with one or more second therapeutic agents.

Drugs covered by this patent

Patent Metadata

Patent number
CA3094079A1
Jurisdiction
CA
Classification
—
Expires
2019-09-26
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.